INB-330 / IN8bio - LARVOL DELTA

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) - "Presented encouraging preclinical data for novel non-signaling CAR (nsCAR) platform and announced the launch of the INB-330 program in AML at the American Association for Cancer Research (AACR) Annual Meeting. Preliminary findings demonstrated that a CD33 targeting nsCAR construct (ns33CAR) was able to selectively differentiate between tumor and healthy tissue, potentially overcoming a critical challenge associated with this previously 'undruggable' target."

Pipeline update • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) - "IN8bio, Inc...announced positive preclinical data for its novel non-signaling CAR (nsCAR) platform and the launch of its INB-330 program in AML. The new data included preliminary results for the nsCAR platform targeting CD33, a challenging but potentially impactful target in AML. The data were presented in a poster session (abstract #1777) at the American Association for Cancer Research (AACR) Annual Meeting 2023...The new data presented at AACR includes early preclinical results for the INB-330 program targeting CD33 for AML, an important but challenging target due to its expression on both leukemic cells and hematopoietic stem cells (HSCs)... These preliminary findings support the ongoing evaluation of INB-330 in AML and improvements in transduction and CAR optimization are ongoing."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology